Acute cytomegalovirus infection associated with pulmonary embolism treated successfully with rivaroxaban: case report
- 65 Downloads
Severe life-threatening thromboembolism may be caused exclusively by the presence of an acute CMV infection or due to the association of this agent and other thrombogenic factors. We report a case of an immunocompetent young female patient who presented a pulmonary embolism associated with acute CMV infection. The patient did not have any other apparent cause of thrombosis. She was successfully treated with rivaroxaban for 6 months without further episodes. To the best of our knowledge, this is the first report of a pulmonary embolism associated with CMV treated with a direct oral anticoagulant. The current case report calls attention to the importance of signs and symptoms of thromboembolism among patients with CMV. Direct oral anticoagulants can potentially bring the same benefits to treat pulmonary embolism associated with CMV as those observed in patients not infected.
KeywordsCytomegalovirus Thromboembolism Rivaroxaban Brazil
We would like to thank Dr. Ricardo Sobhie Diaz, associate professor of the Discipline of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo and Dr. Willi McFarland, associate professor of the Department of Epidemiology and Biostatistics, University of California, San Francisco, for their thoughtful comments and edits.
No funding was received.
Compliance with ethical standards
Conflict of interest
The authors have no potential conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from the individual participant of the study.